Phase 3 Add-On Beats KEYTRUDA Alone but OS and Pricing Bar Remain

Merck and Moderna Announce Positive Phase 3 INTerpath-001 Results for Adjuvant Melanoma

Merck and Moderna announced detailed positive recurrence-free survival (RFS) and distant metastasis-free survival (DMFS) results from the Phase 3 INTerpath-001 trial. The study evaluated intismeran autogene in combination with KEYTRUDA as adjuvant treatment for patients with completely resected stage IIB-IV melanoma. The combination significantly reduced the risk of recurrence or death by 42% (HR=0.58; p<0.001) and the risk of distant metastasis or death by 38% (HR=0.62; p=0.002) compared to KEYTRUDA alone. After six months, a pre-specified sensitivity analysis showed the RFS risk reduction increased to 58%. The safety profile was consistent with previous studies, with no new signals observed.

• Landmark Efficacy in Adjuvant Melanoma: The Phase 3 INTerpath-001 trial demonstrated a highly significant reduction in the risk of recurrence or death by 42% (HR=0.58; p<0.001) and distant metastasis or death by 38% (HR=0.62; p=0.002) for intismeran autogene plus KEYTRUDA compared to KEYTRUDA alone in patients with completely resected stage IIB-IV melanoma, marking a potential foundational shift in treatment.
• Enhanced Benefit Post-Immunization Regimen: A pre-specified sensitivity analysis revealed a more pronounced benefit after the initial six-month intismeran immunization regimen, showing a 58% reduction in the risk of recurrence or death (HR=0.42) and a 50% reduction in distant metastasis or death compared to KEYTRUDA alone. This suggests a delayed but potent immune response from the individualized neoantigen therapy.
• Consistent Safety Profile and Future Outlook: The combination therapy maintained a safety profile generally consistent with previously reported studies, with no new safety signals identified. While overall survival data are not yet mature, a favorable trend has been observed, and the study continues to evaluate this and other key endpoints, with regulatory engagements underway to discuss these significant findings.

Addressing Unmet Needs in Resected Melanoma Adjuvant Treatment

Recent therapeutic advances with BRAF/MEK inhibitors and immune checkpoint inhibitors targeting PD-1, CTLA-4, and emerging pathways have improved survival across disease stages. Despite this progress, durable remissions remain elusive for many patients, with primary and acquired resistance, toxicity, and limited efficacy in rare subtypes continuing to pose significant clinical challenges.

• Poor activity in uveal and other rare subtypes: Uveal melanoma responds poorly to immune checkpoint inhibition (ICI) due to its low tumor mutational burden and PD-1/PD-L1 expression. Anti-CTLA-4 and anti-PD-1/PD-L1 blockade in uveal melanoma have been evaluated with rare responses and no overall survival benefit demonstrated. Tebentafusp, a bispecific T cell engager (TCE) approved for metastatic UM, showed potential in clinical trials, but the objective response rate remains modest. Uveal melanoma poses high potential for liver metastasis, resulting in a median survival of about a year after detection, while acral melanoma has a poor response to immunotherapy and is associated with worse survival, and mucosal melanoma has a poor prognosis and a low mutational burden.

• Adaptive and acquired resistance to targeted therapy: Targeted therapy with BRAF/MEK inhibitors has improved outcomes in patients with BRAF V600-mutant melanoma, resulting in rapid tumor regression and meaningful survival benefits. However, long-term disease control is frequently compromised by adaptive resistance, commonly driven by MAPK pathway reactivation or compensatory PI3K/AKT signaling. Common resistance mechanisms bypass the dependence of tumour cells on initial MAPK pathway driver mutations during targeted therapy.

• Resistance to immunotherapy and need for intensified combinations: Antibodies targeting cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4), programmed cell death (PD)-1, and PD-ligand1 (PD-L1) demonstrated sustained tumour regression in a significant subset of patients, but the majority of patients are either intrinsically resistant or rapidly acquire resistance. Current strategies focus on rational combinations of targeted therapy, checkpoint blockade, IL-2-based approaches, oncolytic viruses, and adoptive cell therapies such as tumor-infiltrating lymphocytes to enhance response depth and durability, but these intensified regimens carry increased toxicity risks, highlighting the need for improved patient selection and monitoring.

• Immune-related toxicities and limited cytotoxic chemotherapy role: Enhancement of the immune response can be accompanied by immune-related adverse events (irAEs), with the most common irAEs being dermatitis, colitis, pneumonitis, hepatitis and endocrinopathies. IrAEs can occur in every organ, even simultaneously, and can occur weeks or months after discontinuation of checkpoint inhibitors, with life-threatening situations occurring. Conventional cytotoxic chemotherapy now plays a limited, largely palliative role given its modest efficacy and substantial toxicity.

• Lack of validated predictive biomarkers: Quantification of predictive power suggested a limited predictive power for single pre-treatment biomarkers, which was improved by early on-treatment biomarkers and combination of predictive biomarkers. For anti-Programmed Death-1/Programmed Death-Ligand 1 checkpoint inhibitors, patients without PD-L1 expression also have a survival benefit, meaning it cannot be used alone to select patients for treatment. A range of other factors including immune infiltration, chemokine signatures, and tumor mutational load have shown an association with treatment outcomes but none of these have been clinically validated as a factor for patient selection.

INTerpath-001: Design and Landmark Efficacy in Melanoma

Key melanoma trials span first-line advanced, neoadjuvant resectable, and refractory settings, evaluating anti-PD-1 monotherapy, ipilimumab plus nivolumab, BRAF/MEK inhibition, and VEGFR inhibition. Designs range from single-arm phase 1-2 studies to randomized phase 3 trials with response, event-free survival, progression-free survival, and overall survival endpoints.

Intismeran's Novel Mechanism and Expanding Clinical Program

The knowledge base does not have sufficient information to answer this question.

Reshaping the Adjuvant Melanoma Treatment Paradigm

In resected stage III melanoma, 12 months of adjuvant pembrolizumab demonstrated sustained benefit over placebo in the phase 3 EORTC1325 / KEYNOTE-054 trial. Among 1019 patients randomized to receive pembrolizumab 200 mg or placebo, intravenously every 3 weeks for a total of 18 doses, recurrence-free survival was longer in the pembrolizumab group than in the placebo group (HR 0.63, 95% CI 0.53 to 0.74), with RFS at 7 years of 50% (95% CI 46% to 55%) in the pembrolizumab and 36% (95% CI 32% to 41%) in the placebo group at median follow-up of 6.9 years. Distant metastasis-free survival was longer in the pembrolizumab group than in the placebo group (HR 0.64, 95% CI 0.54 to 0.76), with DMFS at 7 years of 54% (95% CI 50% to 59%) in the pembrolizumab and 42% (95% CI 37% to 46%) in the placebo group, and progression/recurrence-free survival 2 was longer in the pembrolizumab group than in the placebo group (HR 0.69, 95% CI 0.57 to 0.84).

By contrast, intensification of adjuvant PD-1 blockade with CTLA-4 blockade did not improve efficacy in the randomized, double-blind, phase III CheckMate 915 trial in resected stage IIIB-D or IV melanoma. In 1,833 patients who received nivolumab 240 mg once every 2 weeks plus ipilimumab 1 mg/kg once every 6 weeks (916 patients) or nivolumab 480 mg once every 4 weeks (917 patients) for ≤ 1 year, there was no significant difference between treatment groups for recurrence-free survival in the all-randomly assigned patient population (hazard ratio, 0.92; 95% CI, 0.77 to 1.09; P = .269) or in patients with PD-L1 expression < 1% (hazard ratio, 0.91; 95% CI, 0.73 to 1.14). In all patients, 24-month RFS rates were 64.6% (combination) and 63.2% (nivolumab), while treatment-related grade 3 or 4 adverse events were reported in 32.6% of patients in the combination group and 12.8% in the nivolumab group, with treatment-related deaths reported in 0.4% of patients in the combination group and in no nivolumab-treated patients.

Neoadjuvant investigation has focused on identifying a less toxic but equally effective ipilimumab plus nivolumab schedule in macroscopic stage III melanoma in the multicentre, open-label, phase 2, randomised, controlled OpACIN-neo trial (NCT02977052). Among 86 patients who received at least one dose, grade 3-4 immune-related adverse events within the first 12 weeks were observed in 12 (40%) of 30 patients in group A (two cycles of ipilimumab 3 mg/kg plus nivolumab 1 mg/kg once every 3 weeks intravenously), six (20%) of 30 in group B (two cycles of ipilimumab 1 mg/kg plus nivolumab 3 mg/kg once every 3 weeks intravenously), and 13 (50%) of 26 in group C (two cycles of ipilimumab 3 mg/kg once every 3 weeks directly followed by two cycles of nivolumab 3 mg/kg once every 2 weeks intravenously). Radiological objective response occurred in 19 (63% [95% CI 44-80]) of 30 patients in group A, 17 (57% [37-75]) of 30 in group B, and nine (35% [17-56]) of 26 in group C, while pathological responses occurred in 24 (80% [61-92]) patients in group A, 23 (77% [58-90]) in group B, and 17 (65% [44-83]) in group C.

Personalized mRNA Vaccine Boosts Adjuvant Melanoma Outcomes

The recent announcement regarding the Phase 3 INTerpath-001 trial for intismeran autogene (mRNA-4157/V940) in combination with KEYTRUDA (pembrolizumab) represents a pivotal moment for adjuvant melanoma therapy. For patients with completely resected stage IIB-IV melanoma, the data showing a 42% reduction in recurrence or death and a 38% reduction in distant metastasis or death compared to pembrolizumab alone is highly compelling. This is particularly impactful given that pembrolizumab monotherapy is already a well-established and effective adjuvant treatment, significantly improving recurrence-free and distant metastasis-free survival in both stage IIB/IIC and stage III melanoma. The ability of the individualized neoantigen therapy to further enhance these outcomes suggests a powerful synergistic mechanism, potentially by broadening and deepening the anti-tumor immune response.

This success not only reinforces the therapeutic potential of combining immune checkpoint blockade with personalized mRNA vaccines but also validates the underlying technology. It positions the combination as a strong contender for a new standard of care, offering a differentiated option in a competitive landscape that currently includes other immune checkpoint inhibitors like nivolumab and targeted therapies such as dabrafenib plus trametinib.

However, the path to widespread adoption will involve navigating several critical considerations:

• Manufacturing and Accessibility: The personalized nature of mRNA-4157 necessitates a complex manufacturing process, which historically has involved significant lead times (e.g., 8-16 weeks) and high costs, potentially exceeding $100,000 per patient. While manufacturing innovations are reducing timelines, these factors could create logistical hurdles and impact patient access and reimbursement decisions.

• Long-term Data: While RFS and DMFS benefits are robust, the full long-term impact on overall survival and the sustained durability of response beyond the reported follow-up period will be crucial for comprehensive value assessment.

• Safety Management: Although the safety profile was consistent with previous studies, the combination of two potent immunotherapies requires vigilant management of potential immune-mediated adverse events, which are known to occur with checkpoint inhibitors.

Ultimately, this development underscores the accelerating shift towards highly personalized, immune-driven strategies in oncology. The continued success of mRNA-based vaccines, particularly in combination with established immunotherapies, promises to reshape treatment paradigms and offer new hope for patients facing high-risk cancers.